MNGI Digestive Health is proud to recognize Dr. Van Handel for his recent contributions to groundbreaking research in digestive health, as featured in two national publications.
Dr. Van Handel was a contributing author on a newly published clinical study titled “Mepolizumab Improves Histologic Severity as Measured by the EoEHSS in Adolescents and Adults With Eosinophilic Oesophagitis in a Multicenter, Randomised, Double-Blind, Placebo-Controlled Clinical Trial.” This important research highlights the potential of mepolizumab in treating Eosinophilic Esophagitis and reflects Dr. Van Handel’s commitment to advancing evidence-based care in gastroenterology.
In addition, Dr. Van Handel’s research continues to receive national recognition, with his abstract for the CDI-Scope trial recently accepted for oral presentation at the American College of Gastroenterology (ACG) 2025 Annual Meeting. The abstract, “Significant and Durable Microbiome Restoration in a Phase 3 Trial of Fecal Microbiota, Live-jslm for Recurrent Clostridioides difficile Infection When Administered by Colonoscopy,” will be presented this October in Phoenix, Arizona.
We congratulate Dr. Van Handel for his continued excellence in clinical research and for helping to shape the future of digestive health care.
